Detailansicht

Wissensnetz

Person

Leo Rasche (1980-)

Arzt

Name	Leo Rasche
Zeit	1980- (Lebensdaten)
Ort	Berlin (Geburtsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr. med. habil.
Beruf	Arzt (charakteristischer Beruf) Internist Hämatologe Onkologe
Weitere Angaben	Diss. Univ. Würzburg; Habilitation Fach Innere Medizin an der Medizinischen Fakultät der Uni Würzburg (2020); Facharzt für Innere Medizin und Hämatologie und Onkologie
Quelle	Tumorheterogenität beim Multiplen Myelom und ihr Einfluss auf immuntherapeutische Strategien - 2021 Uni-website, researchgate: https://www.ukw.de/medizinische-klinik-ii/haematologie/team/detail/name/rasche-leo/; https://www.researchgate.net/profile/Leo-Rasche (Stand: 01.08.2022)
Datensatztyp	Person
GND-Nummer	138509298
Datensatz-ID	138509298
Beteiligt an alle anzeigen Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states Real-world analysis of teclistamab in 123 RRMM patients from Germany Elranatamab : bispezifischer BCMA-CD3-Antikörper für Patienten mit rezidiviertem/refraktärem Multiplem Myelom Real-world analysis of teclistamab in 123 RRMM patients from Germany Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1 Gut microbiome alterations in patients with COVID-19-related coagulopathy Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma Chemokine receptor PET/CT provides relevant staging and management changes in marginal zone lymphoma CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors CXCR4-directed PET/CT in 100 patients with marginal zone lymphoma – superior diagnostic performance, predictive potential and eligibility for CXCR4-directed endoradiotherapy [Abstract] The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states Die monoklonale Gammopathie (un) klarer Signifikanz 68Ga-pentixafor PET/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET/CT Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma Novel immunotherapies in multiple myeloma – chances and challenges Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies Tumorheterogenität beim Multiplen Myelom und ihr Einfluss auf immuntherapeutische Strategien COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan 18F-FDG, 11C-methionine, and 68Ga-pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany Exploration of artificial intelligence use with ARIES in multiple myeloma research Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma The link between cytogenetics/genomics and imaging patterns of relapse and progression in patients with relapsed/refractory multiple myeloma: a pilot study utilizing 18F-FDG PET/CT A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration Comparison of 11C-choline and 11C-methionine PET/CT in multiple myeloma Lack of spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: a link to extramedullary hematopoiesis? Kinase domain activation through gene rearrangement in multiple myeloma The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78 Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases Tumortherapie mit Cocktails aus humanen monoklonalen Antikörpern Tumortherapie mit Cocktails aus humanen monoklonalen Antikörpern

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Leo Rasche (1980-)

Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Elranatamab : bispezifischer BCMA-CD3-Antikörper für Patienten mit rezidiviertem/refraktärem Multiplem Myelom

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma

Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1

Gut microbiome alterations in patients with COVID-19-related coagulopathy

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

Chemokine receptor PET/CT provides relevant staging and management changes in marginal zone lymphoma

CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors

CXCR4-directed PET/CT in 100 patients with marginal zone lymphoma – superior diagnostic performance, predictive potential and eligibility for CXCR4-directed endoradiotherapy [Abstract]

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states

Die monoklonale Gammopathie (un) klarer Signifikanz

68Ga-pentixafor PET/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan

Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET/CT

Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Novel immunotherapies in multiple myeloma – chances and challenges

Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Tumorheterogenität beim Multiplen Myelom und ihr Einfluss auf immuntherapeutische Strategien

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan

18F-FDG, 11C-methionine, and 68Ga-pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany

Exploration of artificial intelligence use with ARIES in multiple myeloma research

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

The link between cytogenetics/genomics and imaging patterns of relapse and progression in patients with relapsed/refractory multiple myeloma: a pilot study utilizing 18F-FDG PET/CT

A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration

Comparison of 11C-choline and 11C-methionine PET/CT in multiple myeloma

Lack of spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: a link to extramedullary hematopoiesis?

Kinase domain activation through gene rearrangement in multiple myeloma

The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78

Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases

Tumortherapie mit Cocktails aus humanen monoklonalen Antikörpern

Tumortherapie mit Cocktails aus humanen monoklonalen Antikörpern